Having previously been demonstrated to allow dopamine replenishment, results of a recent clinical trial suggest nilotinib could be a safe and well-tolerated treatment for individuals with Parkinson’s disease.
Browsing: Clinical trials
At the Clinical Trials on Alzheimer’s Disease Congress this week, Biogen (MA, USA) has provided a detailed report on the latest aducanumab results, including why there was such a difference in the results between ENGAGE and EMERGE.
This week in industry includes trials on elenbecestat to be discontinued, ofatumumab demonstrating superiority to Aubagio and the Toca 5 trial results failing to meet primary endpoint.
In this written ‘Ask the Experts’ column, we bring together leaders from our partnered organizations (Alzheimer’s Research UK, Alzheimer’s Society and the UK DRI) to discuss what the future of dementia research might hold.
Ponesimod hits key endpoints in clinical trial for relapsing multiple sclerosis: industry news round-up
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
Whilst at the AD/PD™ conference, we had the pleasure of speaking with Patrik Brundin about his talk on novel therapeutic targets for Parkinson’s disease.
Biogen and Eisai have announced the decision to discontinue the global Phase III trials of aducanumab for Alzheimer’s disease.
Two clinical trials of a combined therapy targeting the opioid system have suggested significant symptom reduction in people with major depression.
Scientists have discovered a vicious feedback loop underlying brain degeneration in Alzheimer’s, which may explain why many drug trials have failed.
Research presented at AAIC reveals the development of the National Strategy and how community based outreach increases participation in Alzheimer’s research.